Debora Barton
Overview
Explore the profile of Debora Barton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reiss K, Angelos M, Dees E, Yuan Y, Ueno N, Pohlmann P, et al.
Nat Med
. 2025 Feb;
PMID: 39920391
Chimeric antigen receptor (CAR) macrophages (CAR-Ms) mediate antitumor immunity via phagocytosis, cytokine release, activation of the tumor microenvironment and antigen presentation. We report results from a non-prespecified interim analysis of...
2.
de Morree E, Vogelzang N, Petrylak D, Budnik N, Wiechno P, Sternberg C, et al.
JAMA Oncol
. 2016 Aug;
3(1):68-75.
PMID: 27560549
Importance: The optimal total number of docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not been investigated yet. It is unknown whether it is beneficial for...
3.
Vogelzang N, Fizazi K, Burke J, de Wit R, Bellmunt J, Hutson T, et al.
Eur Urol
. 2016 Aug;
71(2):168-171.
PMID: 27522164
Patient Summary: Our study in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy, with or without lenalidomide, showed that patient survival was best predicted by circulating tumor cell count...
4.
Yardley D, Brufsky A, Coleman R, Conte P, Cortes J, Gluck S, et al.
Trials
. 2016 Feb;
17:63.
PMID: 26841937
No abstract available.
5.
Yardley D, Brufsky A, Coleman R, Conte P, Cortes J, Gluck S, et al.
Trials
. 2015 Dec;
16:575.
PMID: 26673577
Background: Triple-negative breast cancer is an aggressive disease with unmet clinical needs. In a phase III study of patients with metastatic triple-negative breast cancer, first-line gemcitabine/carboplatin resulted in a median...
6.
Petrylak D, Vogelzang N, Budnik N, Wiechno P, Sternberg C, Doner K, et al.
Lancet Oncol
. 2015 Mar;
16(4):417-25.
PMID: 25743937
Background: Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxel and...